United Therapeutics (UTHR) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum summary

Strategic focus and innovation

• Emphasis on developing medicines, organs, and devices for severe pulmonary and respiratory diseases, including FDA-approved therapies and bioengineered lungs.

• Advanced autologous and xenotransplantation technologies aim to eliminate the need for immunosuppressants in organ transplants.

• R&D targets prolonging time to transplant, with three phase III trials in pulmonary fibrosis and a promising new drug, Tivicel, showing unprecedented efficacy.

• Ralinepag, a once-daily pill for pulmonary hypertension, is expected to become a dominant treatment, with a phase III readout in early next year and potential FDA approval by mid-2027.

• Technology reproprietarization strategy extends product lifecycles by combining proven molecules with novel devices, securing long-term IP protection.

Financial performance and capital allocation

• Achieved 12 consecutive quarters of double-digit growth in both revenues and profits.

• Capital is allocated to internal R&D, business development, and share buybacks, with millions of shares repurchased to return value to investors.

• Currently executing a $1 billion accelerated share repurchase program, reflecting ongoing shareholder feedback and capital review.

Pipeline and regulatory milestones

• Three phase III trials in pulmonary fibrosis, with TETON 2 showing best-in-class results; TETON 1 readout expected early next year.

• Filing for idiopathic pulmonary fibrosis (IPF) drug planned by mid-next year, with anticipated FDA approval by June 2027; potential for earlier approval through ongoing FDA discussions.

• Six new products in stealth mode to be unveiled mid-next year, coinciding with regulatory filings for IPF and Ralinepag.